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Genes
4
What is Gene Therapy?
A technique for correcting defective.(1)
A normal gene inserted to compensate for a nonfunctional gene.(1)
There are approaches:(2)
• An abnormal gene traded for a normal gene
• An abnormal gene repaired through selective reverse mutation
• Change the regulation of gene pairs
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What is Gene Therapy?
 treat, cure, or ultimately prevent disease by changing the expression of 
a person's genes.(3)
 current gene therapy is primarily experimental, with most human 
clinical trials only in the research stages.(4)
Transfer of genetic material to cure a disease or at least to improve the 
clinical status.(4)
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History
The origins is the first live attenuated vaccines in the 1950s.(5)
The concept of gene therapy arose during the 1960s and 1970s.(5)
 In 1972, Theodore Friedmann and Richard Roblin published a paper in 
Science called "Gene therapy for human genetic disease?".(5)
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History
The first attempt at modifying human DNA was performed in 1980 by 
Martin Cline.(6)
 In 1985, Anderson and colleague demonstrated how cells from people 
with ADA deficiency could be modified in tissue culture. (6)
The first successful and approved nuclear gene transfer in humans was 
performed in may 1989 by Dr. Steven Rosenberg.(6)
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History
1990 - The first approved gene therapy clinical trial took 
place when Ashanthi DeSilva, with ADA-deficient 
SeveCombined Immunodeficiencyre.(7)
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How It Works
A vector delivers the therapeutic gene.(8)
The vector’s genetic material is inserted into the target cell.(8)
Functional proteins are created from the therapeutic gene.(8)
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Three types of gene therapy:
Monogenic gene therapy
• Provides genes to encode for the production of a specific protein
• Cystic fibrosis, Muscular dystrophy.(9)
Suicide gene therapy
• Provide ‘suicide’ genes to target cancer cells for destruction(9)
Antisense gene therapy
• Provides a single stranded gene in an’antisense’ orientation to block 
the production of harmful proteins.
• AIDS/HIV(9)
12
challenges in gene therapy(4)
Response Short Lived 
Viral Multi gene Disorders
challenges
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Gene therapy targets
Germ line gene therapy(9)
Somatic cell gene therapy(9)
 Gene augmentation
 Gene replacement
 Specific inhibition of gene expression
 Targeted cell death 
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Gene therapy targets
Gene augmentation
 Add a useful gene into a selected cell type to compensate for the 
missing or flawed version.(10)
 Useful in treating loss of function mutations.(10)
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Gene therapy targets
Gene replacement
 Replaces the mutant copy with a correctly functioning copy in situ.(10)
 Useful for gain of function mutations such as oncogenes.(10)
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Gene therapy targets
Specific inhibition of gene expression
 Involves silencing of specific genes like activated oncogenes.
 Using molecules that degrade RNA transcripts. (10)
 Strategies include 
• Antisense therapy
• siRNA (small interfering RNA)
• Ribozymes
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Gene therapy targets
Targeted cell death
 Tissue specific toxicity as a result of gene therapy.(10)
 Useful in cancer therapy.(10)
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Vectors in genetherapy
 Vectors are carrier molecules which are employed to enhance gene 
transfer efficiency.(11)
 Ability to transduce dividing and non-dividing cells(11)
 Ability to integrate into a site-specific location in the host 
chromosome.(11)
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Vectors in genetherapy
In optimizing a particular vector, one must consider:
Host immune response(12)
Must target specific tissues for long term gene expression(12)
Regulation of the gene after insertion(12)
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Strategies for Transgene Delivery
 In vivo Gene Therapy(4)  Ex vivo Gene Therapy(4)
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Strategies for Transgene Delivery
In vivo Gene Therapy
 intravenous or intramuscular or non-invasive.
 Delivery of new genetic material directly to target cells within the 
body.(4)
Ex vivo Gene Therapy
 target cells are removed from the body and then genetically 
modified.(4)
 The cells are then returned to the body after selection and 
amplification(4)
 This is a safe method but dependent on the type of cells being target.
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Types of vector
Viral  Non-Viral
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Types of vector
Viral vector 
Virus particles provide a relatively efficient.(13)
Viruses are highly evolved natural vectors for the transfer.(13)
 Show some specificity
 Immune reaction
 Possible infection risk
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Types of vector
Viral 
vectors
Popova 
(SV40, 
Polyoma)
Papilloma 
(BPV)
Adeno 
associated 
(AAV)(15)
Adenovirus(14)
Herpes/
Vaccini
aRetroviruses
Lentiviruses
Reovirus
Measles 
virus
Newcastle 
disease 
virus(16)
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Types of vector
Non-viral Vectors
 non-toxic
 no immune response
 Lower tissue specificity
 Less efficient gen transfer 
than viruses
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Types of vector
Non-viral 
Vectors
naked
DNA
amino acid
polymers:
cationic
polymers 
liposomes 
(lipoplexes)
(gene gun) 
Electroporation
Calcium 
phosphate
Retrotrans
posons
Receptor-
mediated 
endocytosis
artificial 
human 
chromosomes 
Gold 
nanomaterials
Iontophoresis
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Types of vector
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Types of vector
Non-viral Vectors
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Types of vector
Non-viral Vectors
Physical 
Methods 
for Gene 
Transfer
magnetofection
Electroporation
genegunSonoporation
Hydrodynamic 
Delivery
Physical        chemical   
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Types of vector
Non-viral vectors
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Types of vector
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Type  of  vectors Integration
To genome
Advantages Disadvantages
Retrovirus Yes -Wide host range.
-high efficiency.
-transduction of dividing cells.
-stable integration.
- infects only once and does not 
replicate in vivo.
-Does not infect non dividing 
-insert size 5-7 kb.
Lentivirus (HIV) Yes -Wide host range. 
-stable transduction of dividing and non 
dividing 
-long term expression.
-nonpathogenic.
-lack of expression of viral proteins.
Advantage and disadvantages of vectors 
Biologic viral vectors
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Type of  
vectors
Integration
To genome
Advantages Disadvantages
Adenovirus No - Transduction of non dividing cells with high efficiency.
-wide host rang.
-high viral titer and high expression levels.
-newly developed gutless vectors have insert size as large as 30
kb.
-Expression of viral proteins 
results in toxic reaction and 
inflammation.
-carcinogenic.
-low efficiency in dividing 
cells.
-short-term expression.
- insert size only 7-11 kb.
Adeno-
associated 
virus
Yes -Transduction of dividing and non dividing cells.
-non immunogenic and nonpathogenic.
-long-term expression of transgene.
-Limited transduction efficiency.
-low efficiency of integration to 
genome.
-small insert size~4-5 kb.
34
Type of  vectors Integration
To genome
Advantages Disadvantages
Herpes simplex virus No -Transduction of neurons and glial 
cells.
-wide host range.
-large insert size up to 30 kb.
-efficient infection.
-Short-term expression.
-spreading of the infection to 
surrounding cell populations. -
-terminally differentiated 
cells.
-immunogenic
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Advantage and disadvantages of vectors Non viral vectors
Vector system Advantages Disadvantages
1-Nacked plasmid DNA -simple, relatively efficient.
-non immunogenic.
-no mutagenesis.
-Transient gene expression.
-DNA not integrated into the genome.
- remain episomal. 
2- Chemical vectors
a-Calcium phosphate 
b-Cationic liposomes
(lipoplex)
c-Polylysine-DNA            
complexes
- Easy to use.
-Non infectious.
-non immunogenic.
-effective for in vivo gene transfer. 
-can carry large DNA fragments.
-Random integration.
-inefficient DNA transfer.
-Unstable.
-remain episomal. 
-poor gene expression.
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Non viral vectors
Vector system Advantages Disadvantages
3- Physical methods
a- Electroporation
b-Gene gun  
c-Microneedle injection
-Easy to use.
-safe.
-Cell receptor independent.
-delivers genes to different tissues. 
-used in vaccine protocols.
-increase gene expression.
-Random integration.
-inefficient DNA transfer. 
-No integration of DNA.
- transient gene expression.
- Ineffective in large surface area.
4-Biologic non viral 
vectors
(human artificial  
chromosomes)
-Stable.
-non-infectious.
-can carry large fragments of DNA.
-non immunogenic.
-no integration into the genome.
- Still in developmental stages.
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Advantage and disadvantages of vectors 
 Integrating versus Non-Integrating Viruses(Viral Vectors)
 Integrating viruses
• Retrovirus (e.g. murine leukemia virus)
• Adeno-associated virus (only 4kbp accommodated)
• Lentivirus
Non-Integrating viruses
• Adenovirus
• Alphavirus
• Herpes Simplex Virus
• Vaccinia
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Non-viral vectors
Liposomes (17)
 not limited by size or number of genes
 safe
 easy to produce
 short-term expression
Diverse manners of ‘lysing’ the liposome
Temperature sensitive
Target sensitive
 pH sensitive
Electric field sensitive
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Liposomes
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Liposomes
 Especially good for in-lung delivery (cystic fibrosis).(18)
 100-1000 times more plasmid DNA needed for the same transfer 
efficiency as for viral vector.(18)
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Electroporation
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Electroporation
 Applying electrical pulses to cellular membranes to increase permeability.(19)
 facilitate the penetration of naked DNA molecules.(19)
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Iontophoresis
 charged molecules move according to an applied low voltage electrical current through a tissue 
within an electrical field.(19)
 Iontophoresis was coupled to intravitreal injection of oligonucleotides.(19)
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Injections of naked DNA
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Amino acid polymers: cationic polymers 
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Ballistic DNA Injection (gene guns)
• Invented for DNA transfer to plant cells
• Fully applicable to eukaryotic cells (4)
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Receptor-mediated endocytosis
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Sonoporation
Uses ultrasonic frequencies to deliver DNA(4)
The process disrupt the cell membrane and allow DNA to move into 
cells.(4)
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Magnetofection
DNA is complexed to a magnetic particles (4)
A magnet is placed underneath the tissue culture dish to bring DNA 
complexes into contact with a cell monolayer.(4)
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Dendrimers
A highly branched macromolecule with a spherical shape.(17)
The surface of the particle may be functionalized in many ways(17)
 In the presence of DNA or RNA charge complimentarity leads to a 
temporary association of the nucleic acid with the cationic dendrimer
Taken into the cell via endocytosis.(4)
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Dendrimers
52
Hybrid methods
Combine two or more techniques.(4)
Virosomes are one example; they combine liposomes with an 
inactivated HIV or influenza virus.(4)
More efficient gene transfer in respiratory epithelial cells than either 
viral or liposomal methods(4)
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Hybrid methods
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Oligonucleotides
 Inactivate the genes involved in the disease process.(20)
One strategy uses antisense specific to the target gene to disrupt the 
transcription of the faulty gene.(20)
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Oligonucleotides
Another uses small molecules of RNA called siRNA.(4)
To signal the cell to cleave specific unique sequences in the mRNA 
transcript of the faulty gene.(4)
Disrupting translation of the faulty mRNA.(4)
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Gold nanomaterials
 Colloidal gold is a suspension consisting of sub-micron gold nanoparticles 
(AuNPs).(17)
 Variety of technologies including microscopy, electronics, diagnostics, and 
therapeutics.(17)
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Hydrodynamic
 A broadly used procedure for DNA and RNA delivery in rodents.(20)
 Serving as a powerful tool for gene/protein drug discovery.(4)
 Gene function analysis, target validation, and identification of elements in 
regulating gene expression.(20)
 Delivery of a variety of molecules including circular DNA(4)
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Hydrodynamic
 HD through mouse tail veins delivers the gene of interest most effectively to the 
mouse liver.(4)
 Successful HD has been achieved in the kidneys, skeletal muscle, myocardium, 
hepatocellular carcinoma, and brain tumor.(4)
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